SG11201407819UA - Improved methods of cell culture for adoptive cell therapy - Google Patents

Improved methods of cell culture for adoptive cell therapy

Info

Publication number
SG11201407819UA
SG11201407819UA SG11201407819UA SG11201407819UA SG11201407819UA SG 11201407819U A SG11201407819U A SG 11201407819UA SG 11201407819U A SG11201407819U A SG 11201407819UA SG 11201407819U A SG11201407819U A SG 11201407819UA SG 11201407819U A SG11201407819U A SG 11201407819UA
Authority
SG
Singapore
Prior art keywords
international
vehicles
cells
therapeutic
native antigen
Prior art date
Application number
SG11201407819UA
Inventor
John R Wilson
Original Assignee
Wolf Wilson Mfg Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/493,768 external-priority patent/US20130115617A1/en
Application filed by Wolf Wilson Mfg Corp filed Critical Wolf Wilson Mfg Corp
Publication of SG11201407819UA publication Critical patent/SG11201407819UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 December 2013 (19.12.2013) WIPOIPCT (10) International Publication Number WO 2013/188427 A1 (51) International Patent Classification: C12N 5/0783 (2010.01) A61K35/12 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/045209 11 June 2013 (11.06.2013) English English (30) Priority Data: 13/493,768 11 June 2012 (11.06.2012) (71) Applicant: WILSON WOLF MANUFACTURING CORPORATION [US/US]; 33 5th Avenue NW, Suite 700, New Brighton, MN 55112 (US). (72) Inventor: WILSON, John, R.; 173 Windsor Lane, New Brighton, MN 55112 (US). (74) Agents: DICKSON, Thomas, G. et al.; Patterson Thuente Pedersen, P.A., 4800 IDS Center, 80 South Eighth Street, Minneapolis, MN 55402-2100 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Ug (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: IMPROVED METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPY l> CJ •t 00 00 i-H en i-H o CJ O £ Fig. 14 A= CONVENTIONAL METHOD • = NOVEL METHOD (57) Abstract: Production and use of novel therapeutic cells, called T-Vehicles, in the allogeneic Adoptive Cell Therapy setting al­ lows a wide range of therapeutic benefits to accrue with minimal or no risk of GVHD. T-Vehicles are created from donor cells that T are altered to contain therapeutic attributes that do not include their native antigen receptors and can deliver therapeutic benefits ir­ relevant of their native antigen specificity. T-Vehicles can possess highly restricted native antigen specificity that renders them un - able recognize antigens present to on normal cells and incapable of initiating GVHD, making them ideal transport vehicles to deliver various therapeutic attributes in vivo. In essence, production and use of T-Vehicles is a paradigm shift that opens the door to thera­ peutic application of cells T in ways not previously contemplated, independent of whether or not there is an HLA match between the donor and the recipient.
SG11201407819UA 2012-06-11 2013-06-11 Improved methods of cell culture for adoptive cell therapy SG11201407819UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/493,768 US20130115617A1 (en) 2009-12-08 2012-06-11 Methods of cell culture for adoptive cell therapy
PCT/US2013/045209 WO2013188427A1 (en) 2012-06-11 2013-06-11 Improved methods of cell culture for adoptive cell therapy

Publications (1)

Publication Number Publication Date
SG11201407819UA true SG11201407819UA (en) 2014-12-30

Family

ID=49758673

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201610387QA SG10201610387QA (en) 2012-06-11 2013-06-11 Improved methods of cell culture for adoptive cell therapy
SG11201407819UA SG11201407819UA (en) 2012-06-11 2013-06-11 Improved methods of cell culture for adoptive cell therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201610387QA SG10201610387QA (en) 2012-06-11 2013-06-11 Improved methods of cell culture for adoptive cell therapy

Country Status (8)

Country Link
EP (1) EP2859093A4 (en)
JP (4) JP2015519080A (en)
CN (2) CN110241086A (en)
AU (3) AU2013274416B2 (en)
CA (1) CA2873608A1 (en)
IL (4) IL288241B2 (en)
SG (2) SG10201610387QA (en)
WO (1) WO2013188427A1 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
WO2013188427A1 (en) * 2012-06-11 2013-12-19 Wilson Wolf Manufacturing Corporation Improved methods of cell culture for adoptive cell therapy
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
CA2907397C (en) 2013-03-15 2022-11-22 Anthrogenesis Corporation Modified t lymphocytes
US20170044496A1 (en) 2014-04-10 2017-02-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
CN106795497A (en) * 2014-08-12 2017-05-31 人类起源公司 It is engineered to go back to the nest to the CAR T lymphocytes of lymph node B cells area, skin or intestines and stomach
CN106755023A (en) * 2015-10-15 2017-05-31 中国人民解放军军事医学科学院附属医院 Chimeric antigen receptor immunocyte with safety switch and preparation method and application
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
NZ750005A (en) 2016-07-07 2023-06-30 Iovance Biotherapeutics Inc Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
CN106119193B (en) * 2016-07-28 2019-10-29 上海闪锦生物科技有限公司 A kind of preparation method for the T cells with antigenic specificity having NK cell speciality concurrently
FI3532607T3 (en) 2016-10-26 2024-03-15 Iovance Biotherapeutics Inc Restimulation of cryopreserved tumor infiltrating lymphocytes
TWI788307B (en) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
AU2017362418B2 (en) 2016-11-17 2024-05-02 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
WO2018129336A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
BR112019013940A2 (en) 2017-01-06 2020-02-11 Iovance Biotherapeutics, Inc. METHOD OF TREATING A CANCER WITH A TUMOR INFILTRANT LYMPHOCYTE POPULATION, PROCESS FOR PREPARING A TUMOR INFILTRANT LYMPHOCYTE POPULATION, TUMOR INFILTRANT LYMPHOCYTE POPULATION, AND, PHARMACEUTICAL COMPOSITION.
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
JOP20190224A1 (en) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20200224161A1 (en) 2017-05-10 2020-07-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2019103857A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
JP2020522516A (en) 2017-06-05 2020-07-30 アイオバンス バイオセラピューティクス，インコーポレイテッド Methods of using tumor-infiltrating lymphocytes in double-resistant melanoma
CR20200251A (en) 2017-11-17 2020-07-17 Iovance Biotherapeutics Inc Til expansion from fine needle aspirates and small biopsies
EP3724885A2 (en) 2017-12-15 2020-10-21 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
BR112020013848A2 (en) 2018-01-08 2020-12-01 Iovance Biotherapeutics, Inc. methods for expanding tumor-infiltrating lymphocytes and for treating an individual with cancer, tumor-infiltrating lymphocyte population, and, method for evaluating transcription factors
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
MX2020010264A (en) 2018-03-29 2020-11-06 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy.
BR112020021660A2 (en) 2018-04-27 2021-02-02 Iovance Biotherapeutics, Inc. methods for expanding tumor infiltrating lymphocytes and for treating an individual with cancer, tumor infiltrating lymphocyte population, and cryopreservation composition
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
TW202031273A (en) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 Treatment of nsclc patients refractory for anti-pd-1 antibody
SG11202101787XA (en) 2018-09-20 2021-04-29 Iovance Biotherapeutics Inc Expansion of tils from cryopreserved tumor samples
EP3877511A1 (en) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
KR20210099573A (en) 2018-11-05 2021-08-12 이오반스 바이오테라퓨틱스, 인크. Selection of improved tumor-reactive T-cells
TW202039830A (en) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
BR112021008549A2 (en) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Method of treating non-small cell lung cancer with a population of tumor-infiltrating lymphocytes
US20220193131A1 (en) 2018-12-19 2022-06-23 Iovance Biotherapeutics, Inc. Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
JP2022553389A (en) 2019-10-25 2022-12-22 アイオバンス バイオセラピューティクス，インコーポレイテッド Gene editing of tumor-infiltrating lymphocytes and its use in immunotherapy
CA3161104A1 (en) 2019-12-11 2021-06-17 Cecile Chartier-Courtaud Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
CA3164986A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
IL297442A (en) 2020-04-22 2022-12-01 Iovance Biotherapeutics Inc Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
TW202208617A (en) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CA3177413A1 (en) 2020-05-04 2021-11-11 Michelle SIMPSON-ABELSON Selection of improved tumor reactive t-cells
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
CA3201818A1 (en) 2020-12-11 2022-06-16 Maria Fardis Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
JP2024500403A (en) 2020-12-17 2024-01-09 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment of cancer with tumor-infiltrating lymphocytes
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
IL307800A (en) 2021-04-19 2023-12-01 Iovance Biotherapeutics Inc Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
AU2022388729A1 (en) 2021-11-10 2024-05-16 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731160A (en) * 1992-05-26 1998-03-24 Rijksuniversiteit Leiden Induction of antigen specific T-lymphocyte responses by stimulation with peptide loaded MHC class I molecules on antigen processing defective mammalian cell lines
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US7745140B2 (en) * 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7638325B2 (en) * 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
MXPA05012080A (en) * 2003-05-08 2006-02-22 Xcyte Therapies Inc Generation and isolation of antigen-specific t cells.
JP5079697B2 (en) * 2005-08-05 2012-11-21 ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハー Method for generating antigen-specific T cells
JP2009213462A (en) * 2008-02-15 2009-09-24 Kist-Europe Forschungs Gmbh Cell modification method and cell modification device
EP3854870A1 (en) * 2009-08-24 2021-07-28 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
JP2013512694A (en) * 2009-12-08 2013-04-18 ウィルソン ウォルフ マニュファクチャリング コーポレイション Methods of culturing cells for adoptive cell therapy
US20130115617A1 (en) * 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
WO2012138858A1 (en) * 2011-04-08 2012-10-11 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
CA2848121C (en) * 2011-09-08 2022-07-05 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
CN104769104A (en) * 2011-12-12 2015-07-08 细胞药物有限公司 Process of expanding t cells
GB201121308D0 (en) * 2011-12-12 2012-01-25 Cell Medica Ltd Process
WO2013119947A1 (en) * 2012-02-09 2013-08-15 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
US20130217122A1 (en) * 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
CN102719399A (en) * 2012-04-28 2012-10-10 北京爱根生物科技有限公司 In vitro amplification method of self-specific T cell, prepared T cell system, pharmaceutical use of cell system and component monitoring method of cell system
WO2013173835A1 (en) * 2012-05-18 2013-11-21 Wilson Wolf Manufacturing Corporation Improved methods of cell culture for adoptive cell therapy
WO2013188427A1 (en) * 2012-06-11 2013-12-19 Wilson Wolf Manufacturing Corporation Improved methods of cell culture for adoptive cell therapy
EP3483276B1 (en) * 2013-09-23 2021-03-31 Wilson Wolf Manufacturing Corporation Improved methods of genetically modifying animal cells
AU2017330379B2 (en) * 2016-09-23 2023-07-13 Memorial Sloan Kettering Cancer Center Generation and use in adoptive immunotherapy of stem cell-like memory T cells
WO2018055191A1 (en) * 2016-09-26 2018-03-29 Tessa Therapeutics Pte. Ltd. T cell expansion method
JP2020527044A (en) * 2017-07-13 2020-09-03 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Methods for enhancing the growth and immunosuppressive capacity of the CD8 + CD45RCLOW / -Treg population
JP2022542968A (en) * 2019-07-29 2022-10-07 ベイラー カレッジ オブ メディスン ANTIGEN-SPECIFIC T-CELL BANK AND METHODS FOR MANUFACTURING THE SAME AND METHODS FOR THERAPEUTIC USE THEREOF
EP4013897A1 (en) * 2019-08-16 2022-06-22 Baylor College of Medicine Third party virus-specific t cell compositions, and methods of making and using the same in anti-viral prophylaxis
US20210371822A1 (en) * 2020-05-27 2021-12-02 University Of Southern California Methods for expanding sars-cov2-antigen-specific t cells, compositions and uses related thereto

Also Published As

Publication number Publication date
JP7244461B2 (en) 2023-03-22
IL235739A0 (en) 2015-01-29
IL288241B2 (en) 2023-10-01
CA2873608A1 (en) 2013-12-19
CN104411819A (en) 2015-03-11
IL235739B (en) 2020-04-30
CN104411819B (en) 2019-05-10
SG10201610387QA (en) 2017-02-27
EP2859093A1 (en) 2015-04-15
JP2018138059A (en) 2018-09-06
IL288241A (en) 2022-01-01
JP2015519080A (en) 2015-07-09
JP2023065668A (en) 2023-05-12
WO2013188427A1 (en) 2013-12-19
IL273719B (en) 2022-01-01
AU2019240684A1 (en) 2019-10-24
AU2013274416A1 (en) 2015-01-15
EP2859093A4 (en) 2016-08-17
AU2013274416B2 (en) 2019-07-04
IL273719A (en) 2020-05-31
IL302514A (en) 2023-07-01
IL288241B1 (en) 2023-06-01
CN110241086A (en) 2019-09-17
JP2020174685A (en) 2020-10-29
AU2022202172A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11201806988UA (en) Improved differentiation method
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201408405WA (en) Engineered three-dimensional connective tissue constructs and methods of making the same
SG11201909331UA (en) Antigen-specific immune effector cells
SG11201407226WA (en) Improved methods of cell culture for adoptive cell therapy
SG11201807188VA (en) Modified cells for immunotherapy
SG11201803701YA (en) Methods and compositions for gene editing in hematopoietic stem cells
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201811405QA (en) Improved differentiation method
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201807489PA (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201805072PA (en) Nicotine powder delivery system
SG11201408124PA (en) Differentiation of human embryonic stem cells into pancreatic endocrine cells
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201811292RA (en) Compositions and methods for the depletion of cells
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201804134YA (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201408261UA (en) Syringe